Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 8 years
- Director since
- 2023
8 years of board service in total across 3 boards, counting each seat separately. Longest: UroGen Pharma Ltd., 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
LB Pharmaceuticals Inc June 3, 202693.4%
-
Keros Therapeutics Inc. June 4, 202581.1%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 12, 2025 | LB Pharmaceuticals Inc | Derivative conversion | +411,681 | — | — |
| Sep 12, 2025 | LB Pharmaceuticals Inc | Open-market purchase | +1,000,000 | $15.00 | $15,000,000 |
| Jun 4, 2025 | Keros Therapeutics Inc. | Grant or award | +5,250 | — | — |
| Jun 16, 2022 | UroGen Pharma Ltd. | Option exercise | +2,211 | $5.00 | $11,055 |
Questions about Ran Nussbaum
What boards is Ran Nussbaum on?
Ran Nussbaum sits on the boards of Keros Therapeutics Inc., LB Pharmaceuticals Inc and UroGen Pharma Ltd.
How long has Ran Nussbaum served on boards?
Our records show at least 8 years of board service across 3 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.